Rafael Fonseca, MD, discusses the integration of biology and treatment selection for patients with newly diagnosed multiple myeloma.
Leif Bergsagel, MD, discusses the treatment evolution for patients with relapsed/refractory multiple myeloma.
The European Commission has approved denosumab for the prevention of skeletal-related events in adult patients with multiple myeloma.
Noa Biran, MD, discusses treatment breakthroughs and emerging advances in the field of multiple myeloma.
Jesus Berdeja, MD, provides an update on practice-changing data for the treatment of patients with multiple myeloma.
Jesus Berdeja, MD, reflects on pivotal studies in multiple myeloma and discussed potential advancements in the upcoming year.
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.
Pomalidomide in combination with low-dose dexamethasone induced an overall response rate of up to 39% in patients with relapsed/refractory multiple myeloma with renal impairment.
Denosumab was noninferior to zoledronic acid in preventing skeletal-related event in patients with newly diagnosed multiple myeloma.
Cristina Gasparetto, MD, discusses selinexor in combination with daratumumab and dexamethasone in patients with relapsed/refractory myeloma.